Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > full enrollment maybe by now ?

<< Previous

Bullboard Posts

Next >>

Comment by samrakon Oct 19, 2020 9:16pm

168 Views

Post# 31745976

RE:RE:RE:RE:full enrollment maybe by now ?

From what I can read of the US portion of the trial, there are outcome measurements, some of which take 28 or in one case 29 days. Certainly there are some outcome measurements at 2 weeks, but I think the trials last until at least mid-November.

<< Previous

Bullboard Posts

Next >>

Record Q3: Equinox Gold achieves commercial production at Greenstone Mine